Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

NEW YORK, April 24, 2019

According to a federal securities lawsuit, Esperion made materially false and misleading statements regarding the Company's business, operational and compliance policies. Esperion made false and/or misleading statements and/or failed to disclose that: (i) Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times.

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid.

Moore Kuehn encourages shareholders to contact Fletcher Moore, Esq. by email at fmoore@moorekuehn.com or telephone at (212) 709-8245.  There is no cost or obligation to you. 

Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers in litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims.  For additional information about Moore Kuehn, please go to www.moorekuehn.com.  ATTORNEY ADVERTISING. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8^th Floor
New York, New York 10005
fmoore@moorekuehn.com
(212) 709-8245